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Recent developments in endoscopic ultrasound-guided 
radiofrequency ablation for pancreatic lesions
Jae Hee Cho*, Sung Ill Jang, and Dong Ki Lee
A  B  S  T  R  A  C  T
Radiofrequency ablation (RFA) has been regarded as an established technique to treat various diseases such as hepatocellular carcinoma, renal cell 
carcinoma and Barret’s esophagus. Although the application of RFA in the pancreas has been limited due to increased risk of adverse events, endo-
scopic ultrasound-guided RFA (EUS-RFA) has generated interest as a novel minimally invasive treatment modality which combines real-time visu-
alization with a precise localization of the treatment procedure. For over a decade, the optimization of RFA devices have made EUS-RFA relatively 
safe, and several studies have supported its feasibility. However, there is insufficient evidence to suggest the appropriate indications and to describe 
long-term outcomes of EUS-RFA for various pancreatic neoplasms such as pancreatic neuroendocrine tumor, ductal adenocarcinoma, and cystic le-
sions. Therefore, this review focuses on the technical aspects and clinical applications of EUS-RFA for each pancreatic disease.
Copyright © 2020, Society of Gastrointestinal Intervention.
Keywords: Endoscopic ultrasound; Pancreatic cystic lesions; Pancreatic neopla; Pancreatic neuroendocrine tumor; Radiofrequency ablation
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Received July 27, 2020; Revised August 31, 2020; Accepted August 31, 2020
* Corresponding author. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, 
Korea.  
E-mail address: jhcho9328@yuhs.ac (J.H. Cho). 
pISSN 2636-0004  eISSN 2636-0012  https://doi.org/10.18528/ijgii200030
 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Surgery is the only potentially successful treatment option for 
various pancreatic neoplasms; however, a minority of these have 
a surgical indication. In pancreatic ductal adenocarcinoma (PDAC), 
only 20% of patients have the opportunity to undergo a surgical 
resection because most patients are diagnosed with unresectable 
disease at presentation. More so, surgery-related morbidity and 
mortality are not negligible. In pancreatic neuroendocrine neo-
plasm (PNEN) and pancreatic cystic lesion (PCL), patients with a 
low malignant potential require life-long surveillance rather than 
extensive surgical resection. Therefore, if some favorable results 
are verified, minimally invasive therapy is very attractive, due to 
safety, reproducibility, and affordability.1 Radiofrequency ablation 
(RFA) is an established minimally invasive therapeutic modality 
for various diseases including hepatocellular carcinoma, renal cell 
carcinoma, and Barret’s esophagus. In pancreatobiliary disease, 
endoscopic retrograde cholangiopancreatography (ERCP)-guided 
intraductal RFA has also been increasingly performed in malig-
nant biliary tract obstruction.2-5 However, the RFA for the pan-
creas is under investigation due to the increased risk of adverse 
events. Because the pancreas is a thermosensitive organ with 
more complex vascular systems, pancreatic neoplasms could in-
filtrate the bile duct or the duodenal wall, encase major vessels, or 
occlude the main pancreatic duct (MPD) by proximity.1 With the 
recent widespread use of endoscopic ultrasound (EUS) which has 
the advantage of real-time visualization and precise localization 
of pancreatic neoplasms, the interest of local ablation through 
EUS is increasing. Therefore, even though several studies have 
showed non-negligible complication rates of EUS-RFA, it is nec-
essary to verify the applicability of EUS-RFA in the management 
algorithms for various pancreatic neoplasms. This review will fo-
cus on the technical aspects of EUS-RFA and clinical applications 
of EUS-RFA for each pancreatic disease.
Technical Aspects
RFA is a technique in which a needle inserted inside a lesion 
causes a hyperthermal injury. The radiofrequency (RF) energy cir-
cuit delivers high-frequency alternating current to produce ionic 
agitation in the cell, resulting in hyperthermia and coagulation 
necrosis in the target tissue.6 RF may be delivered through mo-
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nopolar or bipolar probes. In monopolar probes, a grounding pad 
must be used to close the electrical circuit. In the bipolar mode, 
the circuit is closed inside the probe and current is concentrated 
between the anode and the cathode. Although RFA has already 
been actively applied in pancreatobiliary disease, there have been 
several concerns about possible RFA related adverse events in 
pancreatobiliary disease. For example, ERCP-guided intraductal 
bipolar RFA can ablate the intraluminal biliary tumor with com-
parable safety; however, segmental biliary stricture with cholan-
gitis develops as a long-term result, so biliary stents should be 
placed to maintain biliary drainage after intraductal RFA.7
In terms of technical aspects of EUS-RFA, the fine needle is 
passed through the shortest possible pathway into the normal 
pancreatic parenchyma and avoiding the bile duct, pancreatic 
duct, and major vessels. When RFA energy is applied, the real-
time EUS visualization of bubbles can be seen on the pancreatic 
neoplasm, and these results in a hyperechoic lesion at the end of 
the treatment. After this, RFA electrodes should be repositioned 
during the same session to ablate the untreated area, and this can 
be repeated several times. However, during EUS-RFA, it is difficult 
to accurately estimate the effective area of RFA. Until now, avail-
able EUS probes are the Habib EUS-RFA probe (Boston, Marlbor-
ough, MA, USA), the EUSRA RF electrode (STARmed, Goyang, 
Korea) (Fig. 1) and the HybridTherm (ERBE Elektromedizin GmBH, 
Tübingen, Germany).1 When RFA energy is applied, the amount of 
thermal injury depends on different parameters including power (in 
watts), duration, electrode length, and target temperature. More-
over, a heat sink effect that decreases the efficacy of RFA may 
occur in the area near the blood vessel. Therefore, each safe and 
effective RFA setting according to the various RFA probes should 
be presented.
Radiofrequency Ablation Probe
Habib EUS-RFA and EUSRA are monopolar RFA catheters. 
Habib is a through-the-needle probe and EUSRA is a needle-type 
catheter. The Habib device is a 1 Fr wire monopolar electrode that 
can be inserted into a standard 22G needle and connected to a 
standard electrosurgical unit (ERBE). The EUSRA electrode is an 
19G needle connected to a specific VIVA RF generator (STARmed). 
Typically, this has a pump to cool the EUSRA needle through 
a chilled saline solution. RFA was stopped when automatically 
measured impedance exceeded 1,000 Ω. The performances of 
the two available monopolar EUS-RFA devices have been tested 
recently in the same animal models.8 The technical success was 
100%, and both the devices and the echogenic cloud during the 
application of RF were clearly visible. At histopathologic analysis, 
the extent of tissue necrosis was tissue damage ranging from 3.1 
± 0.4 mm (power = 8 W, effect 4, time = 120 sec) to 2.3 ± 0.1 mm 
(12 W, effect 4, 120 sec) in depth for the Habib probe. Moreover, 
the ablation depth ranged from 3.6 ± 0.5 mm (power = 30 W, 
time = 15 sec) to 3.8 ± 0.4 mm (power = 70 W, time = 11 sec) for 
the EUSRA probe. They showed an effective ablation of pancre-
atic tissue about 2.5 mm around the RFA electrode with both de-
vices and suggested use of 10 W, 120-second ablation settings for 
the Habib EUS-RFA probe and 30 W, 15-second settings for the 
EUSRA when performing EUS-RFA for pancreatic lesions of 5 to 
6 mm. Importantly, the ablation of larger lesions should probably 
require repeated procedures. Interestingly, due to the mechanical 
properties, each device has its own preferences. Since Habib is a 
thin device that is used by putting it inside a needle, it is difficult 
to use repeatedly due to its low durability. On the other hand, EU-
SRA is stiffer and technically difficult to handle in some challeng-
ing areas of the pancreas.8
Different from the aforementioned pure RFA probes, Hybrid-
Therm is a hybrid bipolar needle type probe that is also available 
with cryogenic cooling using carbon dioxide. The probe has a 
sharp distal tip with an active part (1.8 mm in diameter and 20 
mm in length). The bipolar system has the theoretical advantage 
of reducing thermal injury; however, its RFA efficacy is limited. 
In order to overcome the shortcomings, the RFA effect of Hybrid-
Therm is augmented by a cryogenic gas, which increases intersti-
tial devitalization.9 Indirect comparisons with pure RFA indicate 
that a larger ablation zone can be obtained with reduced energy 
and reduced application time. Preclinical studies have shown the 
feasibility of the technique and demonstrated a linear correlation 
between the application time and the size of the ablated tissue, 
when the risk of necrotizing pancreatitis and other adverse events 
increased.10 Complication rates were 43% for minor events and a 
single case of necrotizing pancreatitis, and all complications oc-
curred when applications lasted > 300 seconds. HybridTherm has 
not been actively used yet, so further research is needed for ap-
propriate treatment methods as well as the delivery protocol.
In summary, the limited available clinical experience makes 
it difficult to draw firm conclusions on the standard protocols for 
various EUS-RFA methods. Routine antibiotic prophylaxis and 
administration of rectal nonsteroidal anti-inflammatory drugs are 
now recommended to reduce the EUS-RFA related morbidity and 
mortality.11 Furthermore, the proximity to the MPD has raised 
some doubts on the possibility of safe ablation of these lesions, 
and has led to theoretical advocacy for the possibility of prophy-
lactic pancreatic stenting in these patients.
Clinical Applications
Pancreatic neuroendocrine neoplasm
PNENs are rare neoplasms that account for approximately 2% 
to 3% of primary pancreatic malignancies. The incidence of those 
has increased over the last three decades due to the advancement 
of diagnostic imaging studies as well as widespread awareness by 
physicians. The World Health Organization (WHO) 2010 grading 
system has been proposed to define a new pathologic grade strati-
fication, and the system categorized neuroendocrine tumors (NETs) 
into low-grade (G1), intermediate grade (G2), and high-grade (G3) 
based on their proliferative rate using the mitotic activity and/or 
Insulated
sheath Ablation zone
Fig. 1. EUSRA RF electrode (STARmed, Goyang, Korea).
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a Ki-67 labeling index.12,13 PNEN G3 has a similar prognosis as 
PDAC, but PNEN G1/2 has a better prognosis than PDAC. There-
fore, in PNEN G1/2, debulking surgery is considered as a primary 
therapeutic modality as well as a systemic treatment with a soma-
tostatin analog or a molecular targeted agent. In particular, since 
PNEN G1/2 < 2 cm seems to harbor relatively low progressive 
potential, surveillance is a contemplated strategy to be balanced 
with surgical resection, whose morbidity and mortality seem un-
justified in most cases. For this reason, there have been several 
studies attempting the local ablative treatment instead of simple 
observation in PNENs that are cumbersome to operate. Besides, 
since hyperhormonal symptoms evoked by functional PNENs can 
be controlled through local ablation therapy, the usefulness of 
local treatment can be more justified. Previous experiments of 1 
to 8 patients have been published showing the feasibility of EUS-
RFA in this setting (Table 1).11,14-23
One recent prospective study11 including 14 PNENs (G1, <2 
cm) demonstrated a 6-months success rate of 71%, whereas 85.7% 
of tumors completely disappeared at 12 months, possibly due to 
the late response related to RFA related immunomodulation. Two 
RFA related adverse events of acute necrotic pancreatitis and 
pancreatic duct stricture developed. Another recent study16 also 
evaluated the efficacy of EUS-RFA in 18 patients with PNENs of 
heterogenous prognostic significance (symptomatic insulinomas, 
nonfunctioning G1, small NETs unwilling surveillance, and PNEN 
G3 unfit for surgery). The mean tumor size was 14 mm, with five 
cases having tumors sized between 2 cm and 3 cm. The post-RFA 
ablation area was found in 96% of lesions with one incomplete 
ablation due to its proximity to the MPD on postprocedural EUS 
and computed tomography (CT). Only two cases (11%) of mild 
acute pancreatitis occurred. In another study15 for symptomatic 
PNENs, the complete resolution of hypoglycemia was obtained 
in all seven insulinomas within 1 hour from the RFA, which 
represents a valuable and long-lasting treatment for functioning 
PNENs that are not operable.
Based on the previous results, the appropriate indication for 
EUS-RFA in PNEN can be presented as follows: (1) PNEN patients 
required for surgery but unfit (Fig. 2); (2) hyperhormonal symp-
tom control in small functioning NETs; and (3) small nonfunc-
tioning, G1/2 NETs as an alternative for surveillance.
Pancreatic ductal adenocarcinoma
PDAC is one of the most aggressive malignancies, and a 
leading cause of cancer related mortality. Surgical resection is 
the only curative option; however, only 15% to 20% of patients 
have resectable tumors at initial diagnosis and most patients with 
locally advanced or metastatic PDAC require systemic chemo-
therapy.2 Local ablative therapy including cryotherapy, irrevers-
ible electroporation, stereotactic body radiation therapy, and RFA 
might become potentially relevant in two major indications. One 
is palliation of cancer related symptoms and the other is local dis-
ease control. Although, local ablative therapy has not been helpful 
in improving the outcomes in PDAC, those administrable by EUS 
offer the best combination of excellent real-time visualization 
and precise localization with minimal invasiveness for selective 
ablation of the pancreatic lesions. Therefore, EUS-guided RFA has 
been increasingly employed in experimental and clinical settings 
in PDAC. Moreover, the role of RFA may go beyond local effects 
to the immunomodulation of PDAC that has low immunogenic-
ity. RFA can alter the stroma and the permeability of vessels, and 
activate the adaptive immune response.24
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evaluated. EUS-RFA allows both reduced invasiveness and a real-
time control of the treatment. Furthermore, it is an easily repeat-
able procedure, if necessary. Available experiments of EUS-RFA 
of PDAC include a few small cohorts and focus mainly on techni-
cal feasibility and safety (Table 1).11,14-23 From these researches, 
EUS-RFA is technically feasible and has no major procedure-re-
lated adverse events such as mortality. Most RFA related adverse 
events were minor, such as self-limiting postprocedural abdomi-
nal pain. As for efficacy, when a 30-day CT was executed,18,19 
an ablative necrotic area was identified compared to the original 
tumor volume (between 5.7% and 73.5%).18 However, there are 
several problems in the interpretation of these results. There is a 
lack of data on long-term survival, and the differences between 
the three RFA catheters were not evaluated.
In PDAC, the efficacy of the local treatment has not been 
demonstrated, except for systemic anti-cancer treatment. For this 
reason, even if EUS-RFA is minimally invasive and technically 
feasible, its efficacy must be additionally verified to the validity of 
this procedure. In order to allow the correct positioning of the lo-
cal treatment of EUS-RFA, further efforts should be made to find 
typical molecular characteristics of PDAC in which local ablation 
may be effective. In addition, prospective and controlled studies 
are required in parallel, to compare with systemic chemotherapy 
for the verification of the efficacy of EUS-RFA in PDAC.
Pancreatic cystic lesions
The PCLs are diagnosed with increasing frequency because 
of the widespread use of cross-sectional imaging. Although most 
patients undergo follow-up, in selected cases such as intraductal 
papillary mucinous neoplasms and mucinous neoplasms, serial 
morphologic changes pose an indication for surgery. EUS-guided 
cystic ablation using ethanol and/or an injection of paclitaxel 
has been suggested as an alternative for unfit for surgery patients 
with high risk of a malignant transformation. To date, EUS-RFA 
for PCLs has been proposed, and could provide a better control of 
the ablative area without the risk of fluid spread.
Unlike PDAC and PNEN, previous experiments on PCL are rel-
atively few (Table 1).11,14-23 A prospective study including 17 PCLs 
(mean size, 28 mm; range, 9–60 mm) of 16 intraductal papillary 
mucinous neoplasms with worrisome features and one mucinous 
cystic adenoma unfit for surgery demonstrated a 71% significant 
response rate at 12 months. (11 complete disappearances and one 
partial response in which the diameter was decreased by > 50%). 
In terms of the EUS-RFA technique, they experienced one case of 
jejunal perforation adjacent to a cyst treated without aspirating 
the fluid. EUS-RFA was applied after suction of the liquid from 
the cyst until a thin layer of film remained, to reduce damage to 
collateral structures. After this measure, no further complication 
was experienced. In the entire cohort of 30 patients, also includ-
ing NETs, only 6 (20%) experienced minor events such as mild 
A
B
Fig. 2. Endoscopic ultrasound and Doppler flow 
images. (A) The tip of EUSRA needle was placed 
into the pancreatic neuroendocrine neoplasm (ar-
rows) in head, (B) echogenic cloud around the 
needle during radiofrequency ablation (19 gauge 
EUSRA with 10 mm electrode, power 30 W, dura-
tion 15 seconds) (arrows).
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abdominal pain.
Although the possibility of an effective treatment with EUS 
in PCL has been reported, consensus has not been reached. Since 
Intraductal pancreatic mucinous neoplasm, irrespective of who 
underwent cystic ablation, or required surveillance of the remain-
ing pancreas, there has been a fundamental question of whether 
the treatment of PCLs is necessary. However, in some high-risk 
groups where surgery is difficult, EUS-RFA may be possibly used 
as an alternative solution; more well-designed studies to evaluate 
the safety and long-term efficacy are necessary.
Celiac ganglia neurolysis
Because pancreatic cancer is commonly associated with in-
tense and refractory pain, non-pharmacologic therapies are ad-
ministered with the aim of improving pain control and quality of 
life, while reducing the risks of opioid-induced side effects. Celiac 
plexus neurolysis and block can be performed percutaneously, 
surgically, or under EUS guidance. Among them, EUS-guided 
celiac plexus/ganglia neurolysis using bupivacaine, followed by 
alcohol injection is one of the most established; however, there is 
a possibility of severe adverse effects such as arterial embolism or 
spinal cord infarction due to the migration of ethanol. Recently, 
EUS-RFA has been proposed as a palliative treatment option, 
which allows the accurate control of the ablation zone and there-
fore produces more specific results without severe adverse events. 
A recent randomized controlled trial (RCT)25 comparing EUS-guid-
ed ethanol injection versus RFA for the celiac plexus/ganglia neu-
rolysis using 1 Fr monopolar probe passed via a 19G FNA needle. 
They concluded that EUS-RFA provided more pain relief and less 
severe GI symptoms in patients with pancreatic cancer. However, 
some doubts have arisen on the problem of small sample size and 
risk of the procedures.
Conclusions and Future Perspectives
RF ablation has been regarded as an established technique 
in various disease. Although the application of RFA in the pan-
creas has been limited due to the increased risk of adverse events, 
EUS-RFA has generated interest as a novel minimally invasive 
treatment that combines real-time visualization with precise lo-
calization of the treatment procedure. For over a decade, several 
experiments which support the safety and feasibility regarding 
EUS-RFA have been reported, but the evidence to suggest the ap-
propriate indications and to describe the long-term therapeutic ef-
fects is still lacking. For this reason, various multicenter prospec-
tive studies (NCT0234369262, NCT0369032349, NCT0233667250) 
are being conducted in order to involve EUS-RFA as a part of 
multimodal treatments for the cure of pancreatic malignant and 
premalignant lesions.
In conclusion, EUS-RFA is a technically feasible, safe and 
minimally invasive ablation treatment in selected patients with 
PNEN, PDAC, and PCL. For the verification of each indication of 
EUS-RFA according to various pancreatic neoplasms, future pro-
spective and well-designed controlled studies with longer follow-
up are warranted. Furthermore, while evidence-based answers are 
generated, EUS-RFA should be included within research protocols, 
and centralized in high-volume EUS-centers which have multidis-
ciplinary support.
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